CJC-1295 With Ipamorelin: The Evidence

Two mechanisms, one target

The pair is sold on the idea that two different signals to the pituitary release more growth hormone than either alone. The two molecules do act through different receptors. CJC-1295 is a growth hormone-releasing hormone analog: its developer built it from the first 29 amino acids of the hormone, with four substitutions and a reactive lysine group that attaches to albumin in the blood after injection, which is what gives it a half-life measured in days ^[3]. Ipamorelin is a ghrelin mimetic, a synthetic peptide that acts at the ghrelin receptor instead ^[7].

Their timing differs as much as their targets. In healthy adults, CJC-1295 had an estimated half-life of 5.8 to 8.1 days and kept growth hormone raised for six days or more after one injection ^[1]. Ipamorelin had a terminal half-life of 2 hours and produced a single pulse of growth hormone that peaked at about 40 minutes and then faded ^[8]. Whether combining them adds anything has not been measured in people.

With DAC and without

The name CJC-1295 covers two different molecules in the marketplace. The compound in the published studies is the version with the albumin-binding group, often labeled "with DAC", and its developer's own paper credits that group with keeping it in the blood for days ^[3]. Material sold as "CJC-1295 without DAC" lacks that group, so the multi-day figures in the human studies do not describe it.

No clinical trial in PubMed has tested either version alongside ipamorelin ^[4]. A reader weighing the product sold as the pair is therefore weighing two separate records, one of which may not even concern the molecule in the vial.

The human record for each

CJC-1295 was studied in people in the mid-2000s. Two randomized, placebo-controlled, ascending-dose trials in healthy adults aged 21 to 61 found that a single injection raised growth hormone two- to tenfold for six days or more and IGF-1 1.5- to threefold for 9 to 11 days ^[1]. A second study in healthy men aged 20 to 40 found that the natural pulses of growth hormone survived: their frequency and size were unchanged a week after one injection, while the level between pulses rose 7.5-fold and IGF-1 rose 45 percent ^[2]. A phase 2 trial in adults with HIV-associated abdominal fat, planned for 120 patients, began in December 2005 and was terminated in 2006; the registry states no reason and holds no results ^[5]. No efficacy result for CJC-1295 has ever been published.

Ipamorelin's record is similar in size. A dose-escalation study gave it by infusion to healthy men, eight at each of five rates, and measured the drug and growth hormone in the blood ^[8]. Its one published efficacy trial randomized 114 patients after bowel surgery; the median time to a tolerated meal was 25.3 hours against 32.6 with placebo, a difference that was not statistically significant ^[7]. A second phase 2 trial in the same setting enrolled 320 patients and was completed in 2014, and its registry record holds no posted results ^[11]. The ipamorelin trial review reads the first trial in full.

The combined record

PubMed holds 11 papers that mention CJC-1295 and ipamorelin together, and none is a trial of the pair ^[4]. Nine are narrative articles and reviews published in 2026 on peptide use in sport, orthopedics, aging and aesthetics; the other two are laboratory methods for detecting these peptides in doping control, one of them in seized material ^[4]. ClinicalTrials.gov registers no study of the combination ^[4].

The pairing is therefore a market convention, not a finding. Its rationale, two receptors instead of one, is pharmacology that has not been carried into a controlled comparison, and nothing published shows whether the combination changes the benefit, the harm or neither.

Adverse events as reported

The published human studies report few harms, and none was designed to find uncommon ones. The CJC-1295 trials in healthy adults reported no serious adverse reactions and described the compound as relatively well tolerated ^[1]. In the ipamorelin surgical trial, treatment-emergent adverse events of any kind occurred in 87.5 percent of patients on ipamorelin and 94.8 percent on placebo ^[7].

The FDA's reading of the record is less reassuring. Its Category 2 page states that the agency has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that available clinical data are limited ^[6]. For ipamorelin it cites a published report of serious adverse events, including death, when the drug was given intravenously for gastric motility, and a risk of immune reactions from aggregation or peptide-related impurities ^[6]. No adverse-event data exist for the two taken together.

Legal status of each

Neither molecule has a lawful compounding route. CJC-1295's nomination for the 503A bulks list was withdrawn by its nominators, and the FDA now lists it among the substances whose nominations were withdrawn; it sits on no list ^[6]. The nominations of ipamorelin acetate and ipamorelin free base were withdrawn on September 19, 2024, and when the FDA presented its evaluation to the advisory committee on October 29, 2024 regardless, the committee voted 0–12, with one abstention, against listing each form ^[10]. Under the separate 503B policy for outsourcing facilities, ipamorelin acetate has been in Category 2 since September 29, 2023 ^[6].

Both substances also appear in a federal criminal case. In October 2020 Tailor Made Compounding, a Kentucky pharmacy, pleaded guilty to distributing unapproved new drugs between October 2018 and April 2020; the Justice Department's account of the plea agreement names CJC 1295 and Ipamorelin among them, and the company agreed to forfeit $1,788,906.82, its 2019 sales of those products ^[12]. The plea concerns that one company's distribution, not any seller named in this index.

The CJC-1295 withdrawal review explains why a withdrawn nomination is not a clearance, and the nomination tracker sets the dispositions side by side. In the same GH secretagogues class, sermorelin is the GHRH analog that 503A pharmacies may compound with a prescription, and sermorelin vs tesamorelin compares it with the class's approved drug. Material sold without a prescription as CJC-1295, ipamorelin or the two blended is research-use-only supply, outside pharmacy quality standards.

Elsewhere in this index